The Food and Drug Administration approved DRAXXIN® (tulathromycin) Injectable Solution for the treatment
of BRD associated with Mycoplasma bovis (M. bovis). Clinical studies, field trials, and subsequent real world
experience have proven that DRAXXIN is highly efficacious against BRD caused by mixed bacterial and mycoplasmal
infections.
DRAXXIN offers a broad spectrum of coverage against respiratory pathogens and is indicated for the treatment
of Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and M. bovis. Talk to your veterinarian
about M. bovis and BRD. If M. bovis is present in your region, choose DRAXXIN for your first-line treatment.
Do not use DRAXXIN in female dairy cattle 20 months of age or older. Do not use in calves to be processed for
veal. Effects on reproductive performance, pregnancy and lactation have not been determined.
"DRAXXIN already has a consistently superior record of clinical performance when compared to Baytril, Nuflor
and Micotil1,2,3 in numerous feedyard and stocker studies. DRAXXIN is now the only cattle anti-infective
labeled for the treatment of Mycoplasma bovis respiratory disease. This label claim comes as the result of
demonstrated clinical effectiveness against Mycoplasma bovis in rigorous studies. Veterinarians and producers
should be confident in the fact that no other product has better scientific documentation of effectiveness
against Mycoplasma bovis, or better clinical response to naturally occurring BRD. DRAXXIN is a logical
comprehensive first treatment choice for BRD."
Dan Scruggs, DVM, Diplomat ACVP
Beef Veterinary Operations
Pfizer Animal Health
< Previous | Next - Safety information >